Dianthus Therapeutics (DNTH) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing two clinical-stage autoimmune therapeutics: claseprubart (neuromuscular) and DNTH212 (rheumatology), both with best-in-disease and pipeline-in-a-product potential.

• Claseprubart targets convenient, infrequent subcutaneous self-administration and has shown positive Phase 2 results in gMG, early Phase 3 progress in CIDP, and clinical proof-of-concept in MMN.

• DNTH212 is a bifunctional BDCA2 and BAFF/APRIL inhibitor, demonstrating superior in vitro efficacy and targeting multiple autoimmune diseases with infrequent dosing.

• Strong financial position with ~$1.2B in cash and runway expected into 2030 to fund multiple catalysts.

Claseprubart clinical data and market opportunity

• Phase 2 MaGic trial in gMG showed rapid, sustained, and statistically significant improvements in MG-ADL and QMG scores versus placebo, with robust responder rates and favorable safety profile.

• Over 60% of patients achieved ≥5-point improvement in MG-ADL and QMG; 37% reached minimal symptom expression at Week 13.

• Comparable or superior efficacy to C5 inhibitors and FcRn therapies, with potential for first-line biologic use in large, growing neuromuscular markets (gMG, CIDP, MMN).

• Phase 3 EMERGE trial in gMG and CAPTIVATE in CIDP are ongoing, with top-line data expected in 2H'28 and YE'26, respectively.

Competitive differentiation and safety

• Claseprubart offers upstream complement inhibition, potentially providing broader efficacy and preserving immune function compared to C5 inhibitors.

• Demonstrated favorable safety profile with no boxed warning, REMS, or serious infection signals, differentiating from existing complement inhibitors.

• Designed for patient-friendly, rapid (<10s), self-administered autoinjector dosing every 2 or 4 weeks.